XASX
CLV
Market cap118mUSD
Oct 09, Last price
1.00AUD
1D
-1.96%
1Q
32.45%
Jan 2017
92.31%
Name
Clover Corporation Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Clover Corporation Limited engages in the processing and worldwide sale of natural oils, reaching markets across Australia, New Zealand, Asia, Europe, and the Americas. The company's operations also encompass the creation of encapsulated products and extensive research and development focused on functional food and infant nutrition ingredients. Among its principal offerings are Nu-Mega Hi docosahexaenoic tuna oils, designed for use in infant formula and pharmaceutical goods, alongside its Ocean Gold refined tuna oils. Furthermore, it supplies Nu-Mega Driphorm powders, which are incorporated into various infant formulas, follow-on formulas, growing-up milks, and general food products, as well as Nu-Mega Driphorm HA for non-dairy applications. These products cater to several segments, including active living (for immune and sports support), healthy living (benefiting brain and heart health), and the foundational stages of infant and child development. The company, founded in 1988, maintains its corporate headquarters in Altona North, Australia.
Key people
Non-Executive Chairman of the Board · since 2017
Peter Davey
Chief Executive Officer, Managing Director, Executive Director · since 2014
Andrew Allibon
Chief Financial Officer, Company Secretary · since 2021
Non-Executive Director · since 2025
Toni Brendish
Non-Executive Independent Director · since 2020
Ian Glasson
Non-Executive Independent Director · since 2017
Simon Green
Non-Executive Independent Director · since 2020
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑07 | 2025‑07 | 2024‑07 | 2023‑07 | 2022‑07 | 2021‑07 | 2020‑07 | 2019‑07 | 2018‑07 | 2017‑07 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||